(Q57112739)

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Probable person-to-person transmission of avian influenza A (H5N1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Avian and pandemic influenza: an overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Flu myths: dispelling the myths associated with live attenuated influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Effectiveness of influenza vaccine in health care professionals: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1) by attenuated and inactivated vaccines to A/Chile/83-like viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Influenza vaccine effectiveness among elderly nursing home residents: a cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Current status of live attenuated influenza virus vaccine in the US.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

New technology platforms in the development of vaccines for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

The virosome concept for influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Vaccine delivery methods using viral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Use of viral vectors for the development of vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Safety and immunogenicity of a Proteosome™-trivalent inactivated influenza vaccine, given nasally to healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

DNA vaccines: recent developments and future possibilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Virus-like particles: passport to immune recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Virus-like particles as immunogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

The evolving role of oral insulin in the treatment of diabetes using a novel RapidMist System

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Epidermal powder immunization against influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Virosomal influenza vaccine: a safe and effective influenza vaccine with high efficacy in elderly and subjects with low pre-vaccination antibody titers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illnesses and its social and economic consequences in children aged 3-14 years: a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

A "universal" human influenza A vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

A universal influenza A vaccine based on the extracellular domain of the M2 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Modified M2 proteins produce heterotypic immunity against influenza A virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Antibody response to the M2 protein of influenza A virus expressed in insect cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Evolving strategies for the prevention of influenza infection: potential for multistrain targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Vaccines against avian influenza--a race against time

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Scientific barriers to developing vaccines against avian influenza viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21

Removing barriers to global pandemic influenza vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.21